Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Treatment in Moderate-to-severe Patients Hospitalized for COVID-19
Conditions
Interventions
Famotidine
Celecoxib
+1 more
Start Date
February 7, 2023
Primary Completion Date
February 7, 2023
Completion Date
February 7, 2023
Last Updated
October 10, 2023
NCT05077969
NCT05375773
NCT04470583
Lead Sponsor
Leidos Life Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions